Top 3 Health Care Stocks That Could Blast Off This Month
Top 3 Health Care Stocks That Could Blast Off This Month
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
在醫療保健板塊中，最被超賣的股票提供了一個投資於被低估公司的機會。
The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro.
相對強弱指數（RSI）是一個動量指標，它比較股票在價格上漲天數的強度與價格下跌天數的強度。與股票的價格走勢相比，它可以讓交易者更好地了解股票在開空期的表現。當RSI低於30時，通常認爲資產被超賣，依據Benzinga Pro的說法。
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
以下是該板塊中最新的主要被低估的股票名單，它們的RSI接近或低於30。
Rocket Pharmaceuticals Inc (NASDAQ:RCKT)
Rocket Pharmaceuticals Inc (納斯達克:RCKT)
- On Dec. 11, Rocket Pharmaceuticals announced a $165 million upsized public offering of 13.2 million shares at $12.50 per share. The company's stock fell around 10% over the past month and has a 52-week low of $11.15.
- RSI Value: 26.8
- RCKT Price Action: Shares of Rocket Pharmaceuticals fell 1.3% to close at $12.56 on Friday.
- Benzinga Pro's real-time newsfeed alerted to latest RCKT news.
- 在12月11日，Rocket Pharmaceuticals宣佈了一項價值16500萬的公衆增發，發行1320萬股，價格爲每股12.50美元。該公司的股票在過去一個月中下跌了約10%，並且52周低點爲11.15美元。
- RSI值：26.8
- RCKT價格動態：Rocket Pharmaceuticals的股票週五下跌1.3%，收於12.56美元。
- Benzinga Pro的實時資訊提醒了最新的RCKT消息。
Inovio Pharmaceuticals Inc (NASDAQ:INO)
伊諾維奧製藥公司（納斯達克：INO）
- On Dec. 13, Inovio Pharmaceuticals announced a public offering of 10 million shares for gross proceeds of $30 million.. The company's stock fell around 53% over the past month and has a 52-week low of $1.74.
- RSI Value: 18.5
- INO Price Action: Shares of Inovio Pharmaceuticals gained 7.7% to close at $1.96 on Friday.
- Benzinga Pro's charting tool helped identify the trend in INO stock.
- 在12月13日，伊諾維奧製藥宣佈公開發行1000萬股，粗收益爲3000萬美元。該公司股票在過去一個月下跌了約53%，52周低點爲1.74美元。
- 相對強弱指數（RSI）值：18.5
- INO價格走勢：伊諾維奧製藥的股票在週五上漲了7.7%，收於1.96美元。
- Benzinga Pro的圖表工具幫助識別了INO股票的趨勢。
Outlook Therapeutics Inc (NASDAQ:OTLK)
Outlook Therapeutics Inc（納斯達克：OTLK）
- On Dec. 27, Outlook Therapeutics announced a year-over-year increase in FY24 EPS results. "Over the course of the past year, our team has continued to execute and progress the development of ONS-5010/LYTENAVA in Europe and the United States. Following the receipt of our first positive reimbursement decision worldwide for LYTENAVA from NICE in the United Kingdom, our team continues to make preparations for commercial launch in the UK and Germany, which is expected in the first half of calendar 2025," commented Lawrence Kenyon, Chief Financial Officer and Interim Chief Executive Officer of Outlook Therapeutics. The company's stock fell around 72% over the past six months and has a 52-week low of $0.87.
- RSI Value: 26.9
- OTLK Price Action: Shares of Outlook Therapeutics gained 8.8% to close at $2.24 on Friday.
- Benzinga Pro's signals feature notified of a potential breakout in OTLK shares.
- 在12月27日，Outlook Therapeutics宣佈FY24每股收益結果同比增長。"在過去的一年裏，我們團隊繼續推動ON-5010/LYTENAVA在歐洲和美國的發展。隨着我們在英國首次獲得來自NICE的LYTENAVA正面報銷決策，我們團隊繼續爲在英國和德國的商業推出做好準備，預計將在2025年日歷年上半年實現，"Outlook Therapeutics的財務長和臨時首席執行官Lawrence Kenyon評論道。該公司的股票在過去六個月中下跌了約72%，並且52周最低價爲0.87美元。
- RSI值：26.9
- OTLk價格走勢：Outlook Therapeutics的股票在星期五上漲了8.8%，收於2.24美元。
- Benzinga Pro的信號功能提醒OTLk股票可能出現突破。
Read This Next:
接下來請閱讀：
- Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
- 達美航空的業績即將公佈；這些最準的分析師在業績發佈會前修訂了預測。
譯文內容由第三人軟體翻譯。
